Tomasz M. (Tom) Beer, M.D.
Biography
Tomasz M. Beer holds the Grover C. Bagby Endowed Chair for Prostate Cancer Research and serves as Professor of Medicine, Deputy Director at the Oregon Health & Science University Knight Cancer Institute and Chief Medical Officer of the Center for Early Detection Advanced Research (CEDAR) in Portland, Oregon. Dr. Beer leads the Prostate Cancer Research Program within the OHSU Knight Cancer Institute, an NCI-designated Comprehensive Cancer Center.
He received his medical degree from Johns Hopkins School of Medicine, Baltimore, Maryland, in 1991. He then moved to Oregon Health & Science University. At OHSU he completed his internship and residency in internal medicine and a fellowship in Hematology and Medical Oncology.
As Deputy Director, Dr. Beer contributed to the Knight Cancer Institute achieving Comprehensive Status in 2017 on the heels of a successful $1B philanthropic campaign anchored by a historic $500M challenge gift from Phil and Penny Knight. He has provided oversight to the Cancer Institute’s clinical enterprise, administration, operations, strategic planning, regional partnerships, and clinical research programs, served on institutional leadership committees and represented the institute internally as well with external partners, media, and the public.
As CEDAR Chief Medical Officer, he represents clinicians and patients and provides medical leadership to the OHSU Knight Cancer Institute’s premiere new initiative, a $500M, 10-year program to advance the early detection of lethal cancer.
Dr. Beer has authored and co-authored more than 350 articles and abstracts on prostate cancer largely with a focus on the development of novel therapies through clinical and translational investigation. He co-authored the book Cancer Clinical Trials: A Commonsense Guide to Experimental Cancer Therapies and Clinical Trials. Dr. Beer is particularly known for investigations of targeted therapies and immunotherapies in prostate cancer, including vitamin D receptor, the androgen receptor, and clusterin targeting agents as well as cancer vaccines, CTLA-4 and PD-1 inhibitors, and others. He led the global randomized trial of enzalutamide vs placebo which demonstrated substantial improvements in overall and progression-free survival as well as quality of life and served as the basis for a global change in the standard of care for advanced prostate cancer. Dr. Beer cares for men with prostate cancer at OHSU and at the Portland VA Medical Center.
He received his medical degree from Johns Hopkins School of Medicine, Baltimore, Maryland, in 1991. He then moved to Oregon Health & Science University. At OHSU he completed his internship and residency in internal medicine and a fellowship in Hematology and Medical Oncology.
As Deputy Director, Dr. Beer contributed to the Knight Cancer Institute achieving Comprehensive Status in 2017 on the heels of a successful $1B philanthropic campaign anchored by a historic $500M challenge gift from Phil and Penny Knight. He has provided oversight to the Cancer Institute’s clinical enterprise, administration, operations, strategic planning, regional partnerships, and clinical research programs, served on institutional leadership committees and represented the institute internally as well with external partners, media, and the public.
As CEDAR Chief Medical Officer, he represents clinicians and patients and provides medical leadership to the OHSU Knight Cancer Institute’s premiere new initiative, a $500M, 10-year program to advance the early detection of lethal cancer.
Dr. Beer has authored and co-authored more than 350 articles and abstracts on prostate cancer largely with a focus on the development of novel therapies through clinical and translational investigation. He co-authored the book Cancer Clinical Trials: A Commonsense Guide to Experimental Cancer Therapies and Clinical Trials. Dr. Beer is particularly known for investigations of targeted therapies and immunotherapies in prostate cancer, including vitamin D receptor, the androgen receptor, and clusterin targeting agents as well as cancer vaccines, CTLA-4 and PD-1 inhibitors, and others. He led the global randomized trial of enzalutamide vs placebo which demonstrated substantial improvements in overall and progression-free survival as well as quality of life and served as the basis for a global change in the standard of care for advanced prostate cancer. Dr. Beer cares for men with prostate cancer at OHSU and at the Portland VA Medical Center.